Harmony Biosciences Holdings, Inc. (HRMY) Stock Price & Analysis

Harmony Biosciences Holdings, Inc. (HRMY) rose 0.93% to USD 42.25 as of September 8, 2026 at 06:56 UTC, according to Nexqual real-time market data.

HRMY last closed at USD 42.25; the session ranged USD 41.36–42.34 on volume of 662,547 shares. Market capitalization is —, with a 52-week range of USD 25.52–43.49 (NGM). Source: Nexqual, September 8, 2026 at 06:56 UTC.

Key Statistics (as of September 8, 2026 at 06:56 UTC)

Technical Analysis (HRMY)

Nexqual's technical model rates HRMY "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 06:56 UTC.

From Harmony Biosciences Holdings, Inc.'s Latest SEC 10-K Filing (filed 2026-02-24)

Key Strengths & Strategy (as disclosed to the SEC)

• There are multiple FDA approved therapies for the treatment of DS, LGS or both DS and LGS including, but not limited to, products from Jazz Pharmaceuticals for the treatment of DS and LGS, UCB for the treatment 10 Table of Contents of DS and LGS, Biocodex for the treatment of DS, Eisai Co., Ltd. for the treatment of LGS, Janssen for the treatment of LGS, GlaxoSmithKline for the treatment of LGS, and Assertio Holdings for the treatment of LGS.
• Any patent that issues from these applications is expected to expire in May 2044, not including any possible adjustment to patent term.   Our HBS-102 patent portfolio comprises three patent families.
• For example, third parties may have blocking patents that could be used to prevent us from commercializing our product candidates and practicing our proprietary technology, and our issued patents may be challenged, invalidated or circumvented, which could limit our ability to stop competitors from marketing related products or could limit the term of patent protection that otherwise may exist for our product candidates.
• Our commercial success also depends in part on our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights.

Partnerships

• In July 2022, we entered into a License and Commercialization Agreement with Bioprojet (the "2022 LCA") whereby we obtained exclusive rights to manufacture, develop and commercialize one or more next generation pitolisant based products in the United States and Latin America.
• Next Gen Pitolisant Formulations: Pitolisant Gastro-Resistant and Pitolisant High-Dose In July 2022, we entered into the 2022 LCA with Bioprojet whereby we obtained exclusive rights to manufacture, develop and commercialize one or more new products based on pitolisant in the United States and Latin America, with the potential to add additional indications and formulations upon the agreement of both parties (see "Strategic Agreements" below).

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 06:56 UTC. This page is informational and not investment advice.